Previous 10 | Next 10 |
Abeona Therapeutics (ABEO) announces the activation of a second clinical trial site in its pivotal Phase 3 VIITAL study of its investigational EB-101 treatment for recessive dystrophic epidermolysis bullosa ((RDEB)), a rare connective tissue disorder.Shares up nearly 8% premark...
NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITAL™ study of its investigational EB-101 tre...
gesrey/iStock via Getty Images REGENXBIO ([[RGNX]] +2.5%) has been awarded $28M in damages plus ~$6.1M in interest by an arbitration tribunal in connection with the company’s dispute with Abeona Therapeutics ([[ABEO]] -2.2%) over a licensing agreement. If Abeona does not comply with th...
Best Penny Stocks on Robinhood to Watch Right Now With penny stocks on Robinhood becoming more popular than ever, investors are looking for the best small-caps to buy. One thing to consider is that Robinhood penny stocks tend to be extremely volatile. This is due to both the nature ...
Abeona Therapeutics (ABEO) announces updated Phase 1/2a clinical trial results up to six years following treatment with EB-101 for recessive dystrophic epidermolysis bullosa ((RDEB)).The data showed that investigator assessment of wound healing of 50% or greater from baseline was present in 6...
NEW YORK and CLEVELAND, July 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical trial results up to six years following treatment with Abeona’s investigational EB-101 fo...
At the conclusion of the 2021 Russell indexes annual reconstitution following notable healthcare stocks will join the Russell 3000 Index, effective June 28 after the U.S. market opens.Bionano Genomics (BNGO), Asensus Surgical (ASXC), Ocugen (OCGN), Senseonics Holdings (SEN...
NEW YORK and CLEVELAND, June 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on ...
4 Penny Stocks With Big Gains in 2021 As penny stock investors move into the latter half of the year, there’s no doubting that 2021 has been a wild ride. With the pandemic still in swing, cryptocurrency reaching new heights, and long-term fears of economic inflation abound, it...
Abeona Therapeutics shares rise ([[ABEO]] +6.7%) after the company listed out its achievements during 2020, and provided an update to its strategic goals for the reminder of the current year.In a letter to the company's stockholders, it highlighted some of Abeona's key milestones in 2020:The ...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...